Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial

Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial

Aims Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor modulator balcinrenone in combination with dapagliflozin in a phase 2b study. Meth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of heart failure 2024-08, Vol.26 (8), p.1727-1735
Hauptverfasser: Lam, Carolyn S.P., Køber, Lars, Kuwahara, Koichiro, Lund, Lars H., Mark, Patrick B., Mellbin, Linda G., Schou, Morten, Ely Pizzato, Patricia, Gabrielsen, Anders, Gasparyan, Samvel B., Ghiretti, Alessandro, Hartleib‐Geschwindner, Judith, Housler, Greggory J., Fanti, Paolo, Leonsson‐Zachrisson, Maria, McMurray, John J.V., Solomon, Scott D.
Format: Artikel
Sprache:eng
Schlagworte:
Balcinrenone
Chronic kidney disease
Dapagliflozin
Heart failure
Mineralocorticoid receptor
Urinary albumin‐to‐creatinine ratio
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor modulator balcinrenone in combination with dapagliflozin in a phase 2b study. Methods and results From January 2021 to October 2023, we randomized 133 adults with symptomatic HF, ejection fraction
ISSN:1388-9842
1879-0844
1879-0844
DOI:10.1002/ejhf.3294